Hepatocellular Carcinoma Clinical Trials in Cleveland, Ohio

5 studies are recruiting for hepatocellular carcinoma in Cleveland, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

   This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in pa…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Cleveland, Ohio

   Locations

   219 in total

   Run by

   AstraZeneca

   See if you can join NCT06921785 on ClinicalTrials.gov

2. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Univ Hosp Cleveland /ID# 257706, Cleveland, Ohio

   Locations

   54 in total

   Run by

   AbbVie

   See if you can join NCT06084481 on ClinicalTrials.gov

3. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

   This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tum…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University Hospitals Cleveland Medical Center, Cleveland, Ohio

   Locations

   62 in total

   Run by

   Seagen, a wholly owned subsidiary of Pfizer

   See if you can join NCT05208762 on ClinicalTrials.gov

4. 68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)

   The purpose of this study is to look at the effects (good and bad) of a drug called 177Lu-PSMA-617 (also known as the study drug) when given to participants who have prostate specific membrane antigen (PSMA) positive liver cancer.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, Ohio

   Run by

   Melissa Lumish

   See if you can join NCT06852820 on ClinicalTrials.gov

5. A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

   The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolera…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio

   Locations

   21 in total

   Run by

   Tvardi Therapeutics, Incorporated

   See if you can join NCT05440708 on ClinicalTrials.gov